Immunocore - About the company
Immunocore is a public company based in Abingdon (United Kingdom), founded in 2008 by George Edward Silvanus Robinson, Nicholas John Cross, George Kelly Martin and Bent Jakobsen. It operates as a Developer of bispecific T cell receptor therapies for human diseases. Immunocore has raised $601M in funding from investors like General Atlantic, BlackRock and Woodford Investment Management. The company has 3804 active competitors, including 1279 funded and 897 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Biogen and Abcellera Biologics.
Company Details
Developer of bispecific T cell receptor therapies for human diseases. These therapeutic agents utilize modular technology to modulate immune system activity. The mechanism involves targeting diseased cells to facilitate immune recognition and destruction or reducing immune responses in autoimmune conditions. The research and development focus includes applications for solid tumors, infectious diseases, and autoimmune disorders.
- Website
- www.immunocore.com/
- Social
- Email ID
- *****@immunocore.com
- Registered Address
- Conshohocken, Pennsylvania
Key Metrics
Founded Year
2008
Location
Abingdon, United Kingdom
Stage
Public
Total Funding
$601M in 9 rounds
Latest Funding Round
Investors
Ranked
30th among 3804 active competitors
Annual Revenue
$100M - $500M as on Dec 31, 2025
Employee Count
607 as on Jul 31, 2026
Exit Details
Public
Legal entities associated with Immunocore
Immunocore is associated with 4 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
IMMUNOCORE HOLDINGS PLC CIN: 13119746 , United Kingdom, Active | Jan 06, 2021 | $100M - $500M (As on Dec 31, 2025) | - | |
Immunocore Ltd CIN: 6456207 , United Kingdom, Active | - | 293 (As on Jan 31, 2022) | ||
Immunocore Limited CIN: 6456207 , Germany, Active | Dec 17, 2007 | £10M - £50M (As on Dec 31, 2018) | - | |
IMMUNOCORE, LLC CIN: 900777485 , United States, Active | Dec 31, 1999 | - | 148 (As on Dec 31, 2024) | - |
Immunocore's IPO details
Immunocore got listed on Feb 05, 2021.
Click here to take a look at Immunocore's IPO in detail
Sign up to download Immunocore's company profile
Immunocore's funding and investors
Immunocore has raised a total funding of $601M over 9 rounds. Its first funding round was on Sep 30, 2008. Immunocore has 31 institutional investors and 21 angel investors.
Here is the list of recent funding rounds of Immunocore:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jul 18, 2022 | 4419823 | Post IPO | 2860370 | 7188756 | 3204767 | 1865174 |
Feb 09, 2021 | 4799951 | Post IPO | 3344446 | 7458233 | 8945410 | 2457496 |
Jan 12, 2021 | 4323681 | Series C | 5062222 | 1750652 | 7387248 |
Access funding benchmarks and valuations. Sign up today!View details of Immunocore's funding rounds and investors
Immunocore's founders and board of directors
Founder? Claim ProfileThe founders of Immunocore are George Edward Silvanus Robinson, Nicholas John Cross, George Kelly Martin and Bent Jakobsen. Bahija Jallal is the CEO of Immunocore.
Here are the details of Immunocore's key team members:
- George Edward Silvanus Robinson: Co-Founder of Immunocore. They are also an angel investor in 2 startups and serve on the boards of 4 companies.
- Nicholas John Cross: Co-Founder of Immunocore. They are also an angel investor in 1 startup and serve on the boards of 2 companies.
- George Kelly Martin: Co-Founder of Immunocore. They serve on the boards of 2 companies.
- Bent Jakobsen: Former Co-Founder of Immunocore. They serve on the board of 1 company.
- Bahija Jallal: CEO of Immunocore. They serve on the board of 1 company.
Immunocore's Board of Directors
Immunocore's board has 2 active members. Lily Margaret Hepworth is part of team and Francoise Pauline Webster is independent board member.Here is the list of Immunocore's board of directors:
Name | Type | Representing | Status | Duration |
|---|---|---|---|---|
ojhpfnt | Team | - | Past | 5y 4m |
yskwghk | Team | - | Past | 8y 6m |
uog{zx{ | Team | - | Past | 9y 6m |
whkdacl | Team | - | Past | 8y 7m |
vljymn{ | Team | - | Current | 1y 6m |
sa{gydc | Team | - | Past | 6y 7m |
dfkmljj | Team | - | Past | 9y 4m |
mrzlxlc | Team | - | Past | 5y 5m |
dzkreol | Investor | - | Past | 8y 7m |
j{cezqj | Investor | - | Past | 9y 2m |
Independent board member | - | Current | 5y 5m | |
wr{gdxi | Independent board member | - | Past | 9y 4m |
csirlgj | Independent board member | - | Past | 5y 1m |
pnjuaev | Independent board member | - | Past | 8y 7m |
voqazig | Independent board member | - | Past | 3y 2m |
xshnmgq | Independent board member | - | Past | 7y 4m |
a{ebilq | Independent board member | - | Past | 4y 4m |
bquayqe | Independent board member | - | Past | 4y 2m |
zj{faif | Independent board member | - | Past | 9y 5m |
crhleer | Independent board member | - | Past | 8y 4m |
bbyvnqh | Independent board member | - | Past | 1y 6m |
fvvlrxl | Independent board member | - | Past | 7y 6m |
txcwngl | Independent board member | - | Past | 9y 4m |
wbjyhfj | Independent board member | - | Past | 7y 7m |
axaafot | Independent board member | - | Past | 1y 4m |
yxlprdt | Independent board member | - | Past | 3y 7m |
smtvfwe | Independent board member | - | Past | 2y 1m |
View details of Immunocore's Founder profiles and Board Members
Immunocore's employee count trend
Immunocore has 607 employees as of Jul 26. Here is Immunocore's employee count trend over the years:
Uncover Immunocore's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Immunocore's Competitors and alternates
Top competitors of Immunocore include Jazz Pharmaceuticals, Biogen and Abcellera Biologics. Here is the list of Top 10 competitors of Immunocore, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd |  Biogen 1978, Cambridge (United States), Public | Developer of therapies for neurodegenerative and immunology disorders | $80M | 78/100 | |
3rd |  Abcellera Biologics 2012, Vancouver (Canada), Public | AI-enabled platform for antibodies discovery | $115M | 76/100 | |
4th |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 75/100 | |
5th | Developer of antibody-based drugs to treat autoimmune diseases and cancer | $61.9M | 74/100 | ||
6th | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
7th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 72/100 | |
8th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
9th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
10th | Karyopharm 2008, Newton (United States), Public | Biopharmaceutical company focused on developing and commercializing innovative cancer therapies | $98.4M | 71/100 | |
30th | Immunocore 2008, Abingdon (United Kingdom), Public | Developer of bispecific T cell receptor therapies for human diseases | $601M | 69/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Immunocore's competitors? Click here to see the top ones
Immunocore's Investments and acquisitions
Immunocore has made no investments or acquisitions yet.
Reports related to Immunocore
Here is the latest report on Immunocore's geography:
News related to Immunocore
Filter this listMedia has covered Immunocore for a total of 9 events in the last 1 year, 3 of them have been about company updates and 1 about people movement.
•
Immunocore to report second quarter 2026 financial results and host call on August 6, 2026GlobeNewswire•Jul 30, 2026•Immunocore
•
Immunocore Presents Updated Phase 1 Data of Brenetafusp in Heavily Pretreated Advanced MelanomaGlobeNewswire•May 31, 2026•Immunocore
•
Immunocore reports Phase 1 data for melanoma drug brenetafusp By InvestingInvesting•May 31, 2026•Immunocore
•
Immunocore Reports First Quarter Financial Results and Provides Business UpdateGlobeNewswire•May 06, 2026•Immunocore
•
•
•
•
Immunocore reports Q3 financial results; KIMMTRAK sales up 29% YoYGlobeNewswire•Nov 06, 2025•Immunocore
•
Immunocore Reports Q2 Financial Results, KIMMTRAK® Net Revenues $98 MillionGlobeNewswire•Aug 07, 2025•Immunocore
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Immunocore
Explore our recently published companies
- Wisdom Square Technologies - New Hyde Park based, 2008 founded, Unfunded company
- Fruverpack - Almoradi based, 1992 founded, Unfunded company
- AERA - Bouxwiller based, 1979 founded, Unfunded company
- Divine Hindu - Ujjain based, 2023 founded, Unfunded company
- Globaldigitalpartner.com - 2013 founded, Unfunded company
- OROK - Bourgoin Jallieu based, 2018 founded, Deadpooled company
